FMP
IDEXX Laboratories, Inc.
IDXX
NASDAQ
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
433.25 USD
5.92 (1.37%)
Seeking Alpha
Aug 11, 2024
IDEXX reported lower full-year organic revenue growth due to reduced U.S. clinical visits. Weak consumer sentiment and ongoing staffing challenges may continue to impact clinical visits in the near future. Launch of new menu expansion for Catalyst platform may drive growth in diagnostic business, but the stock remains overvalued.
Seeking Alpha
Aug 6, 2024
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Chris Schott - JPMorgan Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jonathan Block - Stifel David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Second Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being record...
Zacks Investment Research
Aug 6, 2024
IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.
Zacks Investment Research
Aug 6, 2024
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research
Aug 6, 2024
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.44 per share, missing the Zacks Consensus Estimate of $2.87 per share. This compares to earnings of $2.67 per share a year ago.
Zacks Investment Research
Aug 6, 2024
Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.
Seeking Alpha
Aug 6, 2024
This marks the last peak week of the Q2 earnings season with 3,908 companies expected to report. Earnings have come in better-than-expected, but tend to be overshadowed by economic data. Outlier earnings this week include: CSX, CAT, and VFC.
Zacks Investment Research
Aug 5, 2024
MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.
Zacks Investment Research
Aug 1, 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Zacks Investment Research
Jul 22, 2024
IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.